PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: February 14, 2002

(use as many sheets as necessary)

Sheet | 1 | of | 3

Complete if Known	
Application Number	09/920,902
Filing Date	08/03/2001
First Named Inventor	Amine ABINA
Group Art Unit	~~1632~~ 1636
Examiner Name	S. Pappu
Attorney Docket Number	065691-0246

OIPE JC12 FEB 14 2002 PATENT & TRADEMARK OFFICE

RECEIVED FEB 21 2002 TECHCENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
SSP	A1	MOHAMMED-AMINE ABINA, et al., Thrombopoietin (TPO) Knockout Phenotype Induced by Cross-Reactive Antibodies Against TPO Following Injection of Mice with Recombinant Adenovirus Encoding Human TPO, The American Association of Immunologists, (1998), pp. 160, 4481-4489.	
	A2	DONNA ARMENTANO, et al , Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors, Journal of Virology, (March 1997), pp. 2408-2416, Vol. 71, No. 3, American Society for Microbiology.	
	A3	WARREN S. ALEXANDER, et al., Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl, 1996 by the American Society of Hematology. Blood, Vol. 87, No. 6, (March 15, 1996), pp. 2162-2170.	
	A4	DONNA ARMENTANO, et al , Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion, Human Gene Therapy 6:1343-1353 (October 1995).	
	A5	K.L. BERKNER, et al., Expression of Heterologous Sequences in Adenoviral Vectors; Current Topics in Microbiology and Immunology, Vol. 158, Springer-Verlag Berlin-Heidelberg (1992), pp. 39-66.	
	A6	KAREN CARVER-MOORE, et al., Low Levels of Erythroid and Myeloid Progenitors in Thrombopoietin and C mpl - Deficient Mice, The American Society of Hematology, Blood, Vol. 88, No. 3 (August 1, 1996), pp. 803-808.	
	A7	B. FANG, et al., Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression, Human Gene Therapy, (August 1995), pp. 6:1039-1044	
	A8	KRISHNA J. FISHER, et al., Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis, Virology 217, Article No. 0088 (1996), pp. 11-22.	

Examiner Signature	Sita Pappu	Date Considered	04/11/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PATENT & TRADEMARK OFFICE FEB 14 2002 JC

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: February 14, 2002

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/920,902
Filing Date	08/03/2001
First Named Inventor	Amine ABINA
Group Art Unit	~~1632~~ 1636
Examiner Name	S. Pappu
Attorney Docket Number	065691-0246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
SSP	A9	MARIO I. GORZIGLIA, et al., Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy, Journal of Virology, Vol. 70. No. 6 (June 1996), pp. 4173-4178.	
	A10	NICHOLAS M. GOUGH, et al., Structure and Expression of the mRNA for Murine Granulocyte-Macrophage Colony Stimulating Factor, The EMBO Journal, Vol. 4 No. 3 (1985), pp. 645-653.	
	A11	F.L. GRAHAM, et al., Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, J. Gen. Virol., Vol. 36, (1977), pp. 59-72.	
	A12	Z.S. Guo, et al., Evaluation of Promoter Strength for Hepatic Gene Expression In Vivo Following Adenovirus-mediated Gene Transfer, Gene Therapy, Vol. 3, (1996), pp. 802-810.	
	A13	STEFFAN N. HO, et al., Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction, Gene, 77, (1989), pp. 51-59.	
	A14	ZDENEK HOSTOMSKY, et al., High-level Expression of Self-Processed HIV-1 Protease in Escherichia Coli Using a Synthetic Gene, Biochemical and Biophysical Research Communications, Vol. 161, No. 3, (June 30, 1989), pp. 1056-1063.	
	A15	J-L IMLER, et al., Novel Complementation Cell Lines Derived from Human Lung Carcinoma A549 Cells Support the Growth of E1-deleted Adenovirus Vectors, Gene Therapy, Vol. 3, (1996), pp. 75-84.	
	A16	TEMPLE F. SMITH, et al., Comparison of Biosequences, Advances in Applied Mathematics, Vol. 2, (1981), pp. 482-489.	
	A17	DOUGLAS JOLLY, Viral Vector Systems for Gene Therapy, Cancer Gene Therapy, Vol. 1, No. 1, (1994) pp. 51-64.	
	A18	SAUL B. NEEDLEMAN, et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, J. Mol. Biol., Vol. 48, (1970), pp. 443-453.	
	A19	Y. YANG, et al., Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-infected Hepatocytes In Vivo, Gene Therapy, Vol. 3, (1996), pp. 137-144.	
	A20	JOHANNE M. KAPLAN, et al., Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung, Human Gene Therapy, Vol. 8, (January 1, 1997), pp. 45-56.	
	A21	LESLIE D. STRATFORD-PERRICAUDET, et al., Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector, Human Gene Therapy, Vol. 1, (1990), pp. 241-256.	
	A22	YIPING YANG, et al., Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy, Proc. Natl. Acad. Sci. USA, Vol. 91, (May 1994) pp. 4407-4411.	
	A23	RICHARD M. MYERS, et al., A General Method for Saturation Mutagenesis of Cloned DNA Fragments, Science, Vol. 229, (July 19, 1985), pp. 242-247.	

RECEIVED FEB 21 2002 TECH CENTER 1600/2900

Examiner Signature	Sita Pappu	Date Considered	04/11/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC18 FEB 14 2002 PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: February 14, 2002

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/920,902
Filing Date	08/03/2001
First Named Inventor	Amine ABINA
Group Art Unit	~~1632~~ 1636
Examiner Name	S. Pappu
Attorney Docket Number	065691-0246

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
SSP	A24	WILLIAM R. PEARSON, et al., Improved Tools for Biological Sequence Comparison, Proc. Natl. Acad. Sci. USA, Vol. 85, (April 1988) pp. 2444-2448.	
	A25	MARK A. KAY, et al., Long-term Hepatic Adenovirus-mediated Gene Expression in Mice Following CTLA4Ig Administration, Nature Genetics, Vol. 11, (October 1995), pp. 191-197.	
	A26	YIPING YANG, et al., Inactivation of E2a in Recombinant Adenoviruses Improves the Prospect for Gene Therapy in Cystic Fibrosis, Nature Genetics, Vol. 7, (July 1994), pp. 362-369.	
	A27	STEFAN KOCHANEK, et al., A New Adenoviral Vector: Replacement of All Viral Coding Sequences With 28 kb of DNA Independently Expressing Both Full-length Dystrophin and β-galactosidase, Proc. Natl. Acad. Sci. USA, Vol. 93, (June 1996), pp. 5731-5736.	
	A28	SANDEEP K. TRIPATHY, et al., Immune Responses to Transgene-encoded Proteins Limit the Stability of Gene Expression After Injection of Replication-Defective Adenovirus Vectors, Nature Medicine, Vol. 2, No. 5, (May 1996), pp. 545-550.	
	A29	FRANÇOISE WENDLING, et al., c-Mpl Ligand is a Humoral Regulator of Megakaryocytopoiesis, Nature, Vol. 369, (June 16, 1994), pp. 571-574.	
	A30	YIPING YANG, et al., MHC Class I-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses, Immunity, Vol. 1, (August, 1994), pp. 433-442.	
	A31	DOMENICO MAIONE, et al., An Improved Helper-Dependent Adenoviral Vector Allows Persistent Gene Expression After Intramuscular Delivery and Overcomes Preexisting Immunity to Adenovirus, PNAS, Vol. 98, No. 11, (May 22, 2001), pp. 5986-5991.	
	A32	ZSUZSANNA K. ZSENGELLER, et al., Persistence of Replication-Deficient Adenovirus-Mediated Gene Transfer in Lungs of Immune-Deficient (nu/nu) Mice, Human Gene Therapy, Vol. 6, (April 1995) pp. 457-467.	
	A33	ANDRÉ LIEBER, et al., Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo, Journal of Virology, Vol. 70, No. 12, (Dec. 1996), pp. 8944-8960.	
	A34	YIPING YANG, et al., Role of Viral Antigens in Destructive Cellular Immune Responses to Adenovirus Vector-Transduced Cells in Mouse Lungs, Journal of Virology, Vol. 70, No. 10, (October 1996), pp. 7209-7212.	
	A35	DONNA ARMENTANO, et al., Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors, Journal of Virology, Vol 71, No. 3, (March 1997), pp. 2408-2416.	
	A36	YIPING YANG, et al., Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy, Proc. Natl. Acad. Sci. USA, Vol 91, (May 1994), pp. 4407-4411.	
	A37	Y. YANG, et al., Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-Infected Hepatocytes In Vivo, Gene Therapy, Vol. 3, (1996), pp. 137-144.	

RECEIVED FEB 21 2002 TECH CENTER 1600/2900

Examiner Signature	Sita Pappu	Date Considered	04/11/02

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.